Evidence-Based Preoperative Optimization Significantly Reduces Mortality Across High-Risk Surgeries

Surgical patient demographics are undergoing substantial shifts worldwide, with procedural volumes continuing to expand across increasingly complex clinical populations. Major surgery remains the third leading cause of death both in the United States and globally, underscoring the urgent imperative to match each patient with the appropriate procedure in the correct clinical setting. Preoperative medicine has rapidly emerged as a specialized discipline dedicated to conducting comprehensive medical evaluations and optimizing underlying health conditions ahead of operative interventions. Comparative data demonstrate that preoperative evaluations conducted by non-anesthesiology medical physicians, such as cardiologists and primary care doctors, are associated with increased healthcare expenditures, longer hospital stays, and worse postoperative outcomes. Conversely, high-risk and frail patients evaluated in anesthesiology-directed preoperative clinics demonstrate significant clinical improvements, including more days alive at home at thirty and ninety days postoperatively, reduced hospital lengths of stay, lower thirty-day and one-year mortality, and decreased health system costs. Validated risk instruments, including the American Society of Anesthesiologists physical status classification and the American College of Surgeons National Surgical Quality Improvement Program calculator, guide targeted optimization triage, whereas patients undergoing low-risk operations like cataract surgery rarely benefit from routine evaluation.

Cardiovascular complications present severe hazards in surgical care, with perioperative myocardial injury occurring in approximately twenty percent of patients undergoing noncardiac surgery. Ischemic heart disease represents the predominant driver of this myocardial damage. Rather than seeking undiagnosed coronary artery disease, preoperative ischemic assessment aims to identify patients who derive a measurable survival advantage from revascularization, specifically those with left main stenosis or severe multivessel disease coupled with reduced ejection fraction. Stress testing should not reflexively prompt coronary angiography or revascularization unless high-risk features appear. Moderate to large reversible defects show moderate sensitivity for major adverse cardiovascular events, whereas fixed defects do not predict incremental perioperative risk and instead warrant guideline-directed medical therapy. Landmark trials, including ISCHEMIA, COURAGE, and BARI-2D, establish the superiority of guideline-directed medical therapy and demonstrate no benefit from routine revascularization for most patients with chronic coronary disease. Functional capacity provides vital prognostic insight: patients exhibiting poor functional capacity below four metabolic equivalents, or scoring under thirty-four on the Duke Activity Status Index, face elevated perioperative cardiac risk regardless of underlying etiology.

Managing antiplatelet regimens in surgical candidates with coronary stents requires balancing the catastrophic danger of in-stent thrombosis against operative bleeding risks. Perioperative stent thrombosis carries severe morbidity and mortality, where every fifteen-minute interval beyond ninety minutes from ischemic onset to coronary reperfusion doubles patient mortality rates. Current protocols mandate postponing elective surgery and dual-antiplatelet interruption for a minimum of six months following drug-eluting stent placement for stable coronary disease, and twelve months following acute coronary syndromes. For urgent operations where delaying surgery poses greater harm than stent thrombosis, antiplatelet interruption may be considered after three months, provided surgery occurs in centers with immediate interventional cardiology and catheterization services rather than ambulatory centers. In addition, continuing maintenance aspirin across all surgical categories except intracranial and spinal operations is strongly supported by clinical evidence. Sub-analyses from the Perioperative Ischemic Evaluation-2 trial demonstrate that continuing aspirin in patients with coronary stents provides ischemic protection that distinctly outweighs the potential hazards of surgical bleeding.

Heart failure independently elevates perioperative mortality and adverse clinical outcomes threefold compared to isolated coronary artery disease, with systolic dysfunction, reduced ejection fraction, and clinical decompensation carrying acute danger. Transthoracic echocardiography is indicated for patients with heart failure experiencing progressive dyspnea or clinical changes, or lacking objective reassessment within the preceding twelve months. Circulating biomarkers, including B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide, reflect ventricular filling pressures and myocardial wall stress across diverse cardiac and noncardiac conditions. Conversely, normal biomarker concentrations correlate with low rates of major adverse cardiovascular events, often obviating unnecessary testing and effectively ruling out cardiac origins in unexplained dyspnea. In patients with chronic heart failure presenting with elevated baseline peptides, surgery should be deferred until biomarkers return to baseline. Valvular heart disease similarly requires careful preoperative stratification: new murmurs warrant echocardiography, and severe symptomatic aortic stenosis or severe mitral stenosis mandates coordinated cardiologist evaluation or valve intervention prior to elective noncardiac surgery.

Pre-existing cerebrovascular disease presents a persistent perioperative hazard, generating a 1.5-fold to 1.8-fold increase in mortality and a fivefold elevation in major adverse cardiovascular events compared to patients without cerebrovascular history. Although this risk attenuates over time, American College of Cardiology and American Heart Association guidelines recommend delaying noncardiac surgery for at least three months following an acute stroke. All non-emergency procedures must be postponed for at least thirty days following a stroke or transient ischemic attack; however, extending this delay to three months minimizes recurrent stroke risk, and postponing for six months provides maximal reduction in major cardiovascular events. When surgery cannot be delayed for three months, procedures must be restricted to facilities with dedicated stroke-rescue and cardiac-rescue teams to manage potential neurological emergencies. Throughout this timeline, continuation of baseline aspirin therapy remains strongly recommended to protect against recurrent cerebral infarction.

Diabetes mellitus significantly amplifies the risk of surgical site infections, poor wound healing, and cardiovascular complications, particularly when preoperative hemoglobin A1c exceeds 8.0 to 8.5 percent. When time permits, clinical care should be escalated to achieve an A1c below 7.5 percent prior to elective operations. Patients with type 1 diabetes face heightened perioperative volatility, requiring continuous basal insulin to prevent ketoacidosis during fasting and operative stress. Perioperative protocols endorse maintaining continuous glucose monitors and insulin pumps, continuing lowest baseline basal rates rather than holding insulin entirely on the morning of surgery. For conventional subcutaneous regimens, ultralong-acting insulins should be administered at eighty to one hundred percent of usual doses, intermediate-acting neutral protamine Hagedorn or combination formulations reduced to one-third or one-half of the daily dose, and short-acting insulins held until oral nutrition resumes. Reconciling all diabetes medications well in advance of the planned surgery prevents volatile glycemic dysregulation and improves postoperative safety.

Emerging metabolic therapies require specialized perioperative management to prevent severe adverse events. Glucagon-like peptide-1 receptor agonists delay gastric emptying and induce nausea or vomiting, increasing the risk of pulmonary aspiration during anesthesia induction. While early guidance suggested holding these agents for one week preoperatively, this practice often causes rebound hyperglycemia without eliminating delayed gastric emptying; evidence instead supports continuing therapy while adopting an extended fasting regimen of clear liquids up to four hours preoperatively following solid food cessation twenty-four hours in advance. Meanwhile, sodium-glucose co-transporter-2 inhibitors increase renal tubular ketone reabsorption, predisposing surgical patients to euglycemic ketoacidosis under prolonged fasting and surgical stress. To mitigate this hazard, federal guidelines mandate stopping canagliflozin, dapagliflozin, and empagliflozin at least three days before surgery, and ertugliflozin at least four days before surgery, regardless of indication. Conversely, baseline metformin can be safely continued on the day of surgery, though it must be withheld postoperatively if acute kidney injury occurs or following intravenous contrast administration.

Chronic kidney disease markedly magnifies perioperative morbidity, with dialysis-dependent patients experiencing a threefold increase in perioperative myocardial infarction and death compared to individuals with normal renal function. Scheduling elective surgery within twenty-four hours of a hemodialysis session minimizes anticoagulation complications, optimizes intravascular volume, and restores acid-base equilibrium, significantly improving clinical outcomes. In outpatient hemodialysis access procedures, up to fourteen percent of patients display moderate to severe hyperkalemia above 5.7 milliequivalents per liter. However, patients with chronic kidney disease develop cellular adaptations that reduce cardiac susceptibility to arrhythmias compared to individuals experiencing acute hyperkalemia. Because electrocardiography has proven unreliable for screening hyperkalemic cardiac instability, mild potassium elevations below 5.7 milliequivalents per liter do not necessitate cancelling surgery in patients receiving regular maintenance dialysis who are free from metabolic acidosis and have access to postoperative dialysis. Implementing structured coordination policies ensures surgical timing aligns precisely with dialysis schedules to optimize patient stability.

Preoperative anemia independently elevates perioperative mortality, hospital lengths of stay, readmission rates, and transfusion needs, affecting one-third of all surgical candidates globally based on World Health Organization thresholds. Iron deficiency represents the most prevalent nutritional deficiency, affecting 2.4 billion people worldwide, and surgical blood loss, hemodilution, inflammation, and diagnostic phlebotomy exacerbate baseline deficits. Implementing automated reflexive screening pathways, where an extra blood tube triggers an automatic anemia panel when hemoglobin is abnormally low, streamlines rapid diagnosis and facilitates treatment with safe, effective intravenous iron. These optimization strategies coincide with rapid global aging: individuals aged eighty-five and older represent the fastest-growing demographic in the United States, and populations over eighty are projected to triple worldwide by 2050. Projections indicate the median surgical patient age will reach 61.5 years by 2030, with eighty percent of surgical candidates exceeding healthy body mass index thresholds. Addressing hematologic health preoperatively reduces reliance on erythrocyte transfusions that increase postoperative morbidity and infectious complications.

In aging surgical populations, pre-existing cognitive impairment strongly predicts postoperative delirium and long-term functional decline, underscoring the clinical utility of brief validated screening tools such as the Mini-Cog three-word recall and clock-drawing test for patients aged sixty-five and older. In pulmonary medicine, postoperative pulmonary complications occur in up to five percent of noncardiac operations, heavily driven by advanced age and heart failure. While routine pulmonary function testing offers no predictive threshold to preclude non-lung resection surgeries and is not routinely recommended, clinical findings including wheezing, dyspnea, and low oxygen saturation provide superior risk assessment. Finally, acute health events and socioeconomic realities heavily influence outcomes: hospital admissions within thirty days of elective surgery significantly increase postoperative infection rates, while social determinants including poverty, food and housing insecurity, geographic isolation, and limited health literacy exert profound effects on surgical access and overall recovery. Evaluating both physiological vulnerabilities and social determinants ensures a holistic perioperative management strategy tailored to individual risk.

Subject of Research: Evidence-based clinical strategies for preoperative evaluation, risk stratification, and comorbidity optimization before surgery.

Article Title: Preoperative medicine: evaluating and optimizing patients before anesthesia and surgery

Article References: Sweitzer, B. (2026). Preoperative medicine: evaluating and optimizing patients before anesthesia and surgery. Anesthesiology and Perioperative Science, 4(1), Article 9. https://doi.org/10.1007/s44254-025-00134-1

Image Credits: AI Generated

DOI: 10.1007/s44254-025-00134-1

Keywords: Preoperative medicine, Perioperative care, Anesthesiology clinics, Surgical risk stratification, Ischemic heart disease, Heart failure, Valvular heart disease, Dual-antiplatelet therapy, Euglycemic ketoacidosis, GLP-1 receptor agonists, SGLT-2 inhibitors, Chronic kidney disease, Hyperkalemia, Preoperative anemia, Intravenous iron therapy, Mini-Cog screening, Postoperative pulmonary complications, ACS NSQIP calculator